

# Robert D Schreiber

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/627423/robert-d-schreiber-publications-by-citations.pdf>

**Version:** 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

231  
papers

70,058  
citations

113  
h-index

246  
g-index

246  
ext. papers

78,229  
ext. citations

16.2  
avg, IF

7.87  
L-index

| #   | Paper  | IF   | Citations |
|-----|--|------|-----------|
| 231 | Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. <i>Science</i> , <b>2011</b> , 331, 1565-70  | 33.3 | 3816      |
| 230 | Cancer immunoediting: from immunosurveillance to tumor escape. <i>Nature Immunology</i> , <b>2002</b> , 3, 991-8   | 19.1 | 3444      |
| 229 | How cells respond to interferons. <i>Annual Review of Biochemistry</i> , <b>1998</b> , 67, 227-64  | 29.1 | 3365      |
| 228 | Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. <i>Nature</i> , <b>1990</b> , 348, 334-6   | 50.4 | 3318      |
| 227 | Neoantigens in cancer immunotherapy. <i>Science</i> , <b>2015</b> , 348, 69-74   | 33.3 | 2790      |
| 226 | IFN $\gamma$ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. <i>Nature</i> , <b>2001</b> , 410, 1107-11  | 50.4 | 2020      |
| 225 | The immunobiology of cancer immunosurveillance and immunoediting. <i>Immunity</i> , <b>2004</b> , 21, 137-48   | 32.3 | 2015      |
| 224 | The three Es of cancer immunoediting. <i>Annual Review of Immunology</i> , <b>2004</b> , 22, 329-60  | 34.7 | 1946      |
| 223 | Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. <i>Cell</i> , <b>2015</b> , 162, 1229-41  | 56.2 | 1457      |
| 222 | Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. <i>Cell</i> , <b>1996</b> , 84, 431-42   | 56.2 | 1428      |
| 221 | Natural innate and adaptive immunity to cancer. <i>Annual Review of Immunology</i> , <b>2011</b> , 29, 235-71  | 34.7 | 1353      |
| 220 | Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. <i>Nature</i> , <b>2014</b> , 515, 577-81  | 50.4 | 1331      |
| 219 | Batf3 deficiency reveals a critical role for CD8 $\alpha$ <sup>+</sup> dendritic cells in cytotoxic T cell immunity. <i>Science</i> , <b>2008</b> , 322, 1097-100  | 33.3 | 1285      |
| 218 | The molecular cell biology of interferon-gamma and its receptor. <i>Annual Review of Immunology</i> , <b>1993</b> , 11, 571-611  | 34.7 | 1136      |
| 217 | Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1998</b> , 95, 7556-61 | 11.5 | 1126      |
| 216 | Interferons, immunity and cancer immunoediting. <i>Nature Reviews Immunology</i> , <b>2006</b> , 6, 836-48   | 36.5 | 1091      |
| 215 | Adaptive immunity maintains occult cancer in an equilibrium state. <i>Nature</i> , <b>2007</b> , 450, 903-7  | 50.4 | 999       |

|     |   |      |     |
|-----|---|------|-----|
| 214 | Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. <i>Immunity</i> , <b>1996</b> , 4, 25-36  | 32.3 | 947 |
| 213 | Interferon-gamma: the major mediator of resistance against <i>Toxoplasma gondii</i> . <i>Science</i> , <b>1988</b> , 240, 516-8   | 33.3 | 940 |
| 212 | New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape. <i>Current Opinion in Immunology</i> , <b>2014</b> , 27, 16-25  | 7.8  | 882 |
| 211 | The IFN gamma receptor: a paradigm for cytokine receptor signaling. <i>Annual Review of Immunology</i> , <b>1997</b> , 15, 563-91   | 34.7 | 856 |
| 210 | Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. <i>Cell</i> , <b>2002</b> , 109 Suppl, S121-31   | 56.2 | 850 |
| 209 | Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. <i>Nature</i> , <b>2012</b> , 482, 400-4  | 50.4 | 849 |
| 208 | Type I interferon is selectively required by dendritic cells for immune rejection of tumors. <i>Journal of Experimental Medicine</i> , <b>2011</b> , 208, 1989-2003   | 16.6 | 676 |
| 207 | Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. <i>Cell</i> , <b>1998</b> , 93, 373-83   | 56.2 | 675 |
| 206 | The roles of IFN gamma in protection against tumor development and cancer immunoediting. <i>Cytokine and Growth Factor Reviews</i> , <b>2002</b> , 13, 95-109   | 17.9 | 650 |
| 205 | Human complement C3b inactivator: isolation, characterization, and demonstration of an absolute requirement for the serum protein beta1H for cleavage of C3b and C4b in solution. <i>Journal of Experimental Medicine</i> , <b>1977</b> , 146, 257-70 | 16.6 | 641 |
| 204 | Impaired response to interferon-alpha/beta and lethal viral disease in human STAT1 deficiency. <i>Nature Genetics</i> , <b>2003</b> , 33, 388-91  | 36.3 | 634 |
| 203 | Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. <i>Nature Genetics</i> , <b>2016</b> , 48, 607-16   | 36.3 | 613 |
| 202 | Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. <i>Nature Medicine</i> , <b>2014</b> , 20, 1301-9   | 50.5 | 596 |
| 201 | Interleukin 12 signaling in T helper type 1 (Th1) cells involves tyrosine phosphorylation of signal transducer and activator of transcription (Stat)3 and Stat4. <i>Journal of Experimental Medicine</i> , <b>1995</b> , 181, 1755-62                 | 16.6 | 574 |
| 200 | Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. <i>Advances in Immunology</i> , <b>2006</b> , 90, 1-50  | 5.6  | 568 |
| 199 | Decreased sensitivity to tumour-necrosis factor but normal T-cell development in TNF receptor-2-deficient mice. <i>Nature</i> , <b>1994</b> , 372, 560-3  | 50.4 | 533 |
| 198 | Persistent LCMV infection is controlled by blockade of type I interferon signaling. <i>Science</i> , <b>2013</b> , 340, 207-11  | 33.3 | 527 |
| 197 | Anti-Mac-1 selectively inhibits the mouse and human type three complement receptor. <i>Journal of Experimental Medicine</i> , <b>1982</b> , 156, 1000-9   | 16.6 | 527 |

|     |   |      |     |
|-----|---|------|-----|
| 196 | Stat1-dependent and -independent pathways in IFN-gamma-dependent signaling. <i>Trends in Immunology</i> , <b>2002</b> , 23, 96-101  | 14.4 | 477 |
| 195 | Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. <i>Immunity</i> , <b>1994</b> , 1, 447-56  | 32.3 | 464 |
| 194 | Requirement of endogenous interferon-gamma production for resolution of Listeria monocytogenes infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1985</b> , 82, 7404-8   | 11.5 | 452 |
| 193 | A critical function for type I interferons in cancer immunoediting. <i>Nature Immunology</i> , <b>2005</b> , 6, 722-9   | 19.1 | 435 |
| 192 | Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon alpha and interferon gamma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1996</b> , 93, 7673-8   | 11.5 | 426 |
| 191 | Impairment of mycobacterial but not viral immunity by a germline human STAT1 mutation. <i>Science</i> , <b>2001</b> , 293, 300-3  | 33.3 | 419 |
| 190 | Mechanisms of class I restricted immunopathology. A transgenic mouse model of fulminant hepatitis. <i>Journal of Experimental Medicine</i> , <b>1993</b> , 178, 1541-54   | 16.6 | 414 |
| 189 | Evidence for a gamma-interferon receptor that regulates macrophage tumoricidal activity. <i>Journal of Experimental Medicine</i> , <b>1984</b> , 160, 55-74   | 16.6 | 405 |
| 188 | A human IFNGR1 small deletion hotspot associated with dominant susceptibility to mycobacterial infection. <i>Nature Genetics</i> , <b>1999</b> , 21, 370-8  | 36.3 | 402 |
| 187 | Rapid induction of the expression of proto-oncogene fos during human monocytic differentiation. <i>Cell</i> , <b>1985</b> , 40, 209-17  | 56.2 | 380 |
| 186 | Tumor neoantigens: building a framework for personalized cancer immunotherapy. <i>Journal of Clinical Investigation</i> , <b>2015</b> , 125, 3413-21  | 15.9 | 370 |
| 185 | Formation of the initial C3 convertase of the alternative complement pathway. Acquisition of C3b-like activities by spontaneous hydrolysis of the putative thioester in native C3. <i>Journal of Experimental Medicine</i> , <b>1981</b> , 154, 856-67                                | 16.6 | 365 |
| 184 | Defective lymphotoxin-beta receptor-induced NF-kappaB transcriptional activity in NIK-deficient mice. <i>Science</i> , <b>2001</b> , 291, 2162-5  | 33.3 | 360 |
| 183 | Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1994</b> , 91, 3764-8   | 11.5 | 360 |
| 182 | Molecular biology and chemistry of the alternative pathway of complement. <i>Advances in Immunology</i> , <b>1980</b> , 29, 1-53  | 5.6  | 343 |
| 181 | Bone marrow stromal cell antigen 2 is a specific marker of type I IFN-producing cells in the naive mouse, but a promiscuous cell surface antigen following IFN stimulation. <i>Journal of Immunology</i> , <b>2006</b> , 177, 3260-5  | 5.3  | 342 |
| 180 | Synergy between interferon-gamma and tumor necrosis factor-alpha in transcriptional activation is mediated by cooperation between signal transducer and activator of transcription 1 and nuclear factor kappaB. <i>Journal of Biological Chemistry</i> , <b>1997</b> , 272, 14899-907 | 5.4  | 332 |
| 179 | Ligand-induced IFN gamma receptor tyrosine phosphorylation couples the receptor to its signal transduction system (p91).. <i>EMBO Journal</i> , <b>1994</b> , 13, 1591-1600   | 13   | 310 |

|     |   |      |     |
|-----|---|------|-----|
| 178 | Biologic consequences of Stat1-independent IFN signaling. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2001</b> , 98, 6680-5   | 11.5 | 309 |
| 177 | Compensatory dendritic cell development mediated by BATF-IRF interactions. <i>Nature</i> , <b>2012</b> , 490, 502-7   | 50.4 | 293 |
| 176 | Eradication of established tumors by CD8+ T cell adoptive immunotherapy. <i>Immunity</i> , <b>2000</b> , 13, 265-76   | 32.3 | 283 |
| 175 | Effect of tumor necrosis factor alpha on insulin-dependent diabetes mellitus in NOD mice. I. The early development of autoimmunity and the diabetogenic process. <i>Journal of Experimental Medicine</i> , <b>1994</b> , 180, 995-1004      | 16.6 | 281 |
| 174 | CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1999</b> , 96, 8633-8                     | 11.5 | 279 |
| 173 | Partial interferon-gamma receptor 1 deficiency in a child with tuberculoid bacillus Calmette-Guérin infection and a sibling with clinical tuberculosis. <i>Journal of Clinical Investigation</i> , <b>1997</b> , 100, 2658-64               | 15.9 | 279 |
| 172 | Interleukin-10 receptor signaling through the JAK-STAT pathway. Requirement for two distinct receptor-derived signals for anti-inflammatory action. <i>Journal of Biological Chemistry</i> , <b>1999</b> , 274, 16513-21                    | 5.4  | 276 |
| 171 | MHC-II neoantigens shape tumour immunity and response to immunotherapy. <i>Nature</i> , <b>2019</b> , 574, 696-703  | 50.4 | 272 |
| 170 | Natural immunity: a T-cell-independent pathway of macrophage activation, defined in the scid mouse. <i>Immunological Reviews</i> , <b>1991</b> , 124, 5-24  | 11.3 | 271 |
| 169 | Chronic tumor necrosis factor alters T cell responses by attenuating T cell receptor signaling. <i>Journal of Experimental Medicine</i> , <b>1997</b> , 185, 1573-84  | 16.6 | 257 |
| 168 | Deficiency of an erythrocyte membrane protein with complement regulatory activity in paroxysmal nocturnal hemoglobinuria. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1983</b> , 80, 5430-4 | 11.5 | 253 |
| 167 | Stat recruitment by tyrosine-phosphorylated cytokine receptors: an ordered reversible affinity-driven process. <i>Immunity</i> , <b>1995</b> , 2, 677-87  | 32.3 | 251 |
| 166 | Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2008</b> , 105, 652-6                       | 11.5 | 246 |
| 165 | The IkappaB function of NF-kappaB2 p100 controls stimulated osteoclastogenesis. <i>Journal of Experimental Medicine</i> , <b>2003</b> , 198, 771-81   | 16.6 | 234 |
| 164 | Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes?. <i>Current Opinion in Immunology</i> , <b>2007</b> , 19, 203-8   | 7.8  | 232 |
| 163 | Cytokine-related syndrome following injection of anti-CD3 monoclonal antibody: further evidence for transient in vivo T cell activation. <i>European Journal of Immunology</i> , <b>1990</b> , 20, 509-15                                   | 6.1  | 227 |
| 162 | Cancer immunoediting by the innate immune system in the absence of adaptive immunity. <i>Journal of Experimental Medicine</i> , <b>2012</b> , 209, 1869-82  | 16.6 | 221 |
| 161 | Suppressor of cytokine signaling 1 regulates the immune response to infection by a unique inhibition of type I interferon activity. <i>Nature Immunology</i> , <b>2006</b> , 7, 33-9  | 19.1 | 218 |

|     |   |      |     |
|-----|---|------|-----|
| 160 | Type I IFN contributes to NK cell homeostasis, activation, and antitumor function. <i>Journal of Immunology</i> , <b>2007</b> , 178, 7540-9   | 5.3  | 216 |
| 159 | Stat1-independent regulation of gene expression in response to IFN-gamma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2001</b> , 98, 6674-9   | 11.5 | 214 |
| 158 | In vitro megakaryocytopoietic and thrombopoietic activity of c-mpl ligand (TPO) on purified murine hematopoietic stem cells. <i>Blood</i> , <b>1994</b> , 84, 4045-4052   | 2.2  | 214 |
| 157 | Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy. <i>Annals of the New York Academy of Sciences</i> , <b>2013</b> , 1284, 1-5   | 6.5  | 207 |
| 156 | Immune-mediated dormancy: an equilibrium with cancer. <i>Journal of Leukocyte Biology</i> , <b>2008</b> , 84, 988-93  | 6.5  | 205 |
| 155 | Blocking monoclonal antibodies specific for mouse IFN-alpha/beta receptor subunit 1 (IFNAR-1) from mice immunized by in vivo hydrodynamic transfection. <i>Journal of Interferon and Cytokine Research</i> , <b>2006</b> , 26, 804-19 | 3.5  | 197 |
| 154 | Toll-like receptor-dependent production of IL-12p40 causes chronic enterocolitis in myeloid cell-specific Stat3-deficient mice. <i>Journal of Clinical Investigation</i> , <b>2003</b> , 111, 1297-308                                | 15.9 | 197 |
| 153 | Ligand-induced autoregulation of IFN-gamma receptor beta chain expression in T helper cell subsets. <i>Science</i> , <b>1995</b> , 270, 1215-8  | 33.3 | 177 |
| 152 | Gamma interferon limits access of <i>Listeria monocytogenes</i> to the macrophage cytoplasm. <i>Journal of Experimental Medicine</i> , <b>1989</b> , 170, 2141-6  | 16.6 | 174 |
| 151 | Fourth component of human complement: description of a three polypeptide chain structure. <i>Journal of Experimental Medicine</i> , <b>1974</b> , 140, 1324-35  | 16.6 | 174 |
| 150 | Stat3 recruitment by two distinct ligand-induced, tyrosine-phosphorylated docking sites in the interleukin-10 receptor intracellular domain. <i>Journal of Biological Chemistry</i> , <b>1996</b> , 271, 27954-61                     | 5.4  | 171 |
| 149 | Gains of glycosylation comprise an unexpectedly large group of pathogenic mutations. <i>Nature Genetics</i> , <b>2005</b> , 37, 692-700   | 36.3 | 168 |
| 148 | Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape. <i>Cancer Immunology Research</i> , <b>2017</b> , 5, 106-117   | 12.5 | 162 |
| 147 | Distinct and complementary functions of MDA5 and TLR3 in poly(I:C)-mediated activation of mouse NK cells. <i>Journal of Experimental Medicine</i> , <b>2009</b> , 206, 2967-76  | 16.6 | 162 |
| 146 | A role for the immunological synapse in lineage commitment of CD4 lymphocytes. <i>Nature</i> , <b>2004</b> , 431, 527-32  | 50.4 | 157 |
| 145 | Partial interferon-gamma receptor signaling chain deficiency in a patient with bacille Calmette-Guérin and <i>Mycobacterium abscessus</i> infection. <i>Journal of Infectious Diseases</i> , <b>2000</b> , 181, 379-84                | 7    | 152 |
| 144 | High-Dimensional Analysis Delineates Myeloid and Lymphoid Compartment Remodeling during Successful Immune-Checkpoint Cancer Therapy. <i>Cell</i> , <b>2018</b> , 175, 1014-1030.e19   | 56.2 | 150 |
| 143 | Bactericidal activity of the alternative complement pathway generated from 11 isolated plasma proteins. <i>Journal of Experimental Medicine</i> , <b>1979</b> , 149, 870-82   | 16.6 | 145 |

|     |   |      |     |
|-----|---|------|-----|
| 142 | Monoclonal antibodies specific for murine p55 and p75 tumor necrosis factor receptors: identification of a novel in vivo role for p75. <i>Journal of Experimental Medicine</i> , <b>1995</b> , 181, 607-17  | 16.6 | 142 |
| 141 | Initiation of the alternative pathway of complement: recognition of activators by bound C3b and assembly of the entire pathway from six isolated proteins. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1978</b> , 75, 3948-52 | 11.5 | 141 |
| 140 | CD8(+) dendritic cells are an obligate cellular entry point for productive infection by <i>Listeria monocytogenes</i> . <i>Immunity</i> , <b>2011</b> , 35, 236-48  | 32.3 | 140 |
| 139 | Novel STAT1 alleles in otherwise healthy patients with mycobacterial disease. <i>PLoS Genetics</i> , <b>2006</b> , 2, e131  | 6    | 138 |
| 138 | Phosphorylated interferon-alpha receptor 1 subunit (IFN $\alpha$ R1) acts as a docking site for the latent form of the 113 kDa STAT2 protein.. <i>EMBO Journal</i> , <b>1996</b> , 15, 1064-1074  | 13   | 138 |
| 137 | Macrophage activation: priming activity from a T-cell hybridoma is attributable to interferon-gamma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1983</b> , 80, 3782-6  | 11.5 | 138 |
| 136 | Interferon $\alpha$ and Its Important Roles in Promoting and Inhibiting Spontaneous and Therapeutic Cancer Immunity. <i>Cold Spring Harbor Perspectives in Biology</i> , <b>2019</b> , 11,  | 10.2 | 138 |
| 135 | Type I interferons are essential mediators of apoptotic death in virally infected cells. <i>Genes To Cells</i> , <b>1998</b> , 3, 29-37   | 2.3  | 135 |
| 134 | IFN unresponsiveness in LNCaP cells due to the lack of JAK1 gene expression. <i>Cancer Research</i> , <b>2005</b> , 65, 3447-53   | 10.1 | 130 |
| 133 | HBSAg retention sensitizes the hepatocyte to injury by physiological concentrations of interferon-gamma. <i>Hepatology</i> , <b>1992</b> , 16, 655-63   | 11.2 | 130 |
| 132 | IFN-producing cells respond to CXCR3 ligands in the presence of CXCL12 and secrete inflammatory chemokines upon activation. <i>Journal of Immunology</i> , <b>2002</b> , 169, 6079-83   | 5.3  | 128 |
| 131 | Type I interferon negatively controls plasmacytoid dendritic cell numbers in vivo. <i>Journal of Experimental Medicine</i> , <b>2011</b> , 208, 2367-74   | 16.6 | 124 |
| 130 | ERK1 and ERK2 activate CCAAAT/enhancer-binding protein-beta-dependent gene transcription in response to interferon-gamma. <i>Journal of Biological Chemistry</i> , <b>2001</b> , 276, 287-97  | 5.4  | 124 |
| 129 | STAT1-deficient mice spontaneously develop estrogen receptor $\beta$ -positive luminal mammary carcinomas. <i>Breast Cancer Research</i> , <b>2012</b> , 14, R16  | 8.3  | 122 |
| 128 | Perforin and granzymes have distinct roles in defensive immunity and immunopathology. <i>Immunity</i> , <b>2006</b> , 25, 835-48  | 32.3 | 122 |
| 127 | Interleukin-12 and B7.1 co-stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors. <i>European Journal of Immunology</i> , <b>1996</b> , 26, 1335-41  | 6.1  | 122 |
| 126 | The Role of Neoantigens in Naturally Occurring and Therapeutically Induced Immune Responses to Cancer. <i>Advances in Immunology</i> , <b>2016</b> , 130, 25-74   | 5.6  | 119 |
| 125 | Ligand-induced assembly and activation of the gamma interferon receptor in intact cells. <i>Molecular and Cellular Biology</i> , <b>1996</b> , 16, 3214-21  | 4.8  | 117 |

|     |  |      |     |
|-----|--|------|-----|
| 124 | DNA double-strand breaks activate a multi-functional genetic program in developing lymphocytes. <i>Nature</i> , <b>2008</b> , 456, 819-23  | 50.4 | 115 |
| 123 | WDFY4 is required for cross-presentation in response to viral and tumor antigens. <i>Science</i> , <b>2018</b> , 362, 694-699  | 33.3 | 115 |
| 122 | Blockade of interferon Beta, but not interferon alpha, signaling controls persistent viral infection. <i>Cell Host and Microbe</i> , <b>2015</b> , 17, 653-61  | 23.4 | 114 |
| 121 | HIF-1alpha regulates epithelial inflammation by cell autonomous NFkappaB activation and paracrine stromal remodeling. <i>Blood</i> , <b>2008</b> , 111, 3343-54  | 2.2  | 114 |
| 120 | Baculovirus stimulates antiviral effects in mammalian cells. <i>Journal of Virology</i> , <b>1999</b> , 73, 9944-51  | 6.6  | 114 |
| 119 | Timing and magnitude of type I interferon responses by distinct sensors impact CD8 T cell exhaustion and chronic viral infection. <i>Cell Host and Microbe</i> , <b>2012</b> , 11, 631-42  | 23.4 | 113 |
| 118 | Definition of target antigens for naturally occurring CD4(+) CD25(+) regulatory T cells. <i>Journal of Experimental Medicine</i> , <b>2005</b> , 201, 681-6  | 16.6 | 111 |
| 117 | CD8 T cells can protect against an intracellular bacterium in an interferon gamma-independent fashion. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1992</b> , 89, 11612-6                      | 11.5 | 108 |
| 116 | Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction. <i>Cell</i> , <b>2020</b> , 183, 818-834.e13  | 56.2 | 105 |
| 115 | Interferon-gamma and cancer immunoediting. <i>Immunologic Research</i> , <b>2005</b> , 32, 231-45  | 4.3  | 104 |
| 114 | Requirement for T cells and effect of lymphokines in successful chemotherapy for an intracellular infection. Experimental visceral leishmaniasis. <i>Journal of Clinical Investigation</i> , <b>1989</b> , 83, 1253-7                          | 15.9 | 103 |
| 113 | Altered erythrocyte C3b receptor expression, immune complexes, and complement activation in homosexual men in varying risk groups for acquired immune deficiency syndrome. <i>Journal of Clinical Investigation</i> , <b>1986</b> , 78, 977-82 | 15.9 | 102 |
| 112 | Consensus nomenclature for CD8 T cell phenotypes in cancer. <i>Oncotmunology</i> , <b>2015</b> , 4, e998538  | 7.2  | 101 |
| 111 | IFN-gamma action on pancreatic beta cells causes class I MHC upregulation but not diabetes. <i>Journal of Clinical Investigation</i> , <b>1998</b> , 102, 1249-57  | 15.9 | 100 |
| 110 | Identification of a functionally important sequence in the C terminus of the interferon-gamma receptor. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1992</b> , 89, 11706-10                    | 11.5 | 98  |
| 109 | Interaction of target cell-bound C3bi and C3d with human lymphocyte receptors. Enhancement of antibody-mediated cellular cytotoxicity. <i>Journal of Experimental Medicine</i> , <b>1981</b> , 153, 1592-603                                   | 16.6 | 98  |
| 108 | Properdin- and nephritic factor-dependent C3 convertases: requirement of native C3 for enzyme formation and the function of bound C3b as properdin receptor. <i>Journal of Experimental Medicine</i> , <b>1975</b> , 142, 760-72               | 16.6 | 98  |
| 107 | Role of cytokines (interleukin 1, tumor necrosis factor, and transforming growth factor beta) in natural and lipopolysaccharide-enhanced radioresistance. <i>Journal of Experimental Medicine</i> , <b>1991</b> , 173, 1177-82                 | 16.6 | 97  |



|     |  |      |    |
|-----|--|------|----|
| 106 | TREM2 Modulation Remodels the Tumor Myeloid Landscape Enhancing Anti-PD-1 Immunotherapy. <i>Cell</i> , <b>2020</b> , 182, 886-900.e17  | 56.2 | 95 |
| 105 | cDC1 prime and are licensed by CD4 T cells to induce anti-tumour immunity. <i>Nature</i> , <b>2020</b> , 584, 624-629  | 50.4 | 94 |
| 104 | Cloning and expression of the cDNA for the murine interferon gamma receptor. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1989</b> , 86, 8497-501   | 11.5 | 93 |
| 103 | A causative relationship between mutant IFNGR1 alleles and impaired cellular response to IFNgamma in a compound heterozygous child. <i>American Journal of Human Genetics</i> , <b>1998</b> , 62, 723-6                                    | 11   | 90 |
| 102 | Interleukin 1 participates in the development of anti-Listeria responses in normal and SCID mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1992</b> , 89, 1011-5                        | 11.5 | 90 |
| 101 | Antibody-independent activation of the alternative complement pathway by measles virus-infected cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1980</b> , 77, 559-62                   | 11.5 | 88 |
| 100 | Opposing effects of toll-like receptor (TLR3) signaling in tumors can be therapeutically uncoupled to optimize the anticancer efficacy of TLR3 ligands. <i>Cancer Research</i> , <b>2010</b> , 70, 490-500                                 | 10.1 | 87 |
| 99  | Comparative analysis of regulatory and effector T cells in progressively growing versus rejecting tumors of similar origins. <i>Cancer Research</i> , <b>2006</b> , 66, 7301-9   | 10.1 | 87 |
| 98  | Paroxysmal nocturnal hemoglobinuria: deficiency in factor H-like functions of the abnormal erythrocytes. <i>Journal of Experimental Medicine</i> , <b>1983</b> , 157, 1971-80  | 16.6 | 86 |
| 97  | IFN-dependent down-regulation of the NKG2D ligand H60 on tumors. <i>Journal of Immunology</i> , <b>2006</b> , 176, 905-13  | 5.3  | 85 |
| 96  | A temporal role of type I interferon signaling in CD8+ T cell maturation during acute West Nile virus infection. <i>PLoS Pathogens</i> , <b>2011</b> , 7, e1002407   | 7.6  | 84 |
| 95  | A molecular concept of the properdin pathway. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1976</b> , 73, 612-6   | 11.5 | 84 |
| 94  | Regulation of IFN-alpha/beta genes: evidence for a dual function of the transcription factor complex ISGF3 in the production and action of IFN-alpha/beta. <i>Genes To Cells</i> , <b>1996</b> , 1, 995-1005                               | 2.3  | 83 |
| 93  | Interferon gamma signals via a high-affinity multisubunit receptor complex that contains two types of polypeptide chain. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1995</b> , 92, 5401-5 | 11.5 | 83 |
| 92  | Anti-IFN- $\gamma$ receptor antibody treatment ameliorates disease in lupus-predisposed mice. <i>Journal of Immunology</i> , <b>2012</b> , 189, 5976-84  | 5.3  | 82 |
| 91  | IFN-gamma controls the generation/activation of CD4+ CD25+ regulatory T cells in antitumor immune response. <i>Journal of Immunology</i> , <b>2005</b> , 175, 4433-40  | 5.3  | 82 |
| 90  | Tissue-specific targeting of cytokine unresponsiveness in transgenic mice. <i>Immunity</i> , <b>1995</b> , 3, 657-66   | 32.3 | 81 |
| 89  | Identification of an interferon-gamma receptor alpha chain sequence required for JAK-1 binding. <i>Journal of Biological Chemistry</i> , <b>1996</b> , 271, 9-12   | 5.4  | 77 |

|    |  |      |    |
|----|--|------|----|
| 88 | Opposing roles for IL-23 and IL-12 in maintaining occult cancer in an equilibrium state. <i>Cancer Research</i> , <b>2012</b> , 72, 3987-96  | 10.1 | 76 |
| 87 | Demonstration and partial characterization of the interferon-gamma receptor on human mononuclear phagocytes. <i>Journal of Clinical Investigation</i> , <b>1985</b> , 76, 2196-205                         | 15.9 | 76 |
| 86 | CANCER. The odds of immunotherapy success. <i>Science</i> , <b>2015</b> , 350, 158-9   | 33.3 | 70 |
| 85 | Vav proteins control MyD88-dependent oxidative burst. <i>Blood</i> , <b>2007</b> , 109, 3360-8   | 2.2  | 67 |
| 84 | Anti-tumor necrosis factor modulates anti-CD3-triggered T cell cytokine gene expression in vivo. <i>Journal of Clinical Investigation</i> , <b>1994</b> , 93, 2189-96                                      | 15.9 | 67 |
| 83 | Purification and characterization of the human interferon-gamma receptor from placenta. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1988</b> , 85, 4837-41 | 11.5 | 66 |
| 82 | Lysis of measles virus-infected cells by the purified cytolytic alternative complement pathway and antibody. <i>Journal of Experimental Medicine</i> , <b>1979</b> , 150, 445-54                           | 16.6 | 66 |
| 81 | Ligand-induced formation of p55 and p75 tumor necrosis factor receptor heterocomplexes on intact cells. <i>Journal of Biological Chemistry</i> , <b>1997</b> , 272, 10784-9                                | 5.4  | 65 |
| 80 | Critical role for interferon regulatory factor 3 (IRF-3) and IRF-7 in type I interferon-mediated control of murine norovirus replication. <i>Journal of Virology</i> , <b>2012</b> , 86, 13515-23          | 6.6  | 64 |
| 79 | A critical role for type I IFN in arthritis development following <i>Borrelia burgdorferi</i> infection of mice. <i>Journal of Immunology</i> , <b>2008</b> , 181, 8492-503                                | 5.3  | 62 |
| 78 | Raji cell injury and subsequent lysis by the purified cytolytic alternative pathway of human complement. <i>Clinical Immunology and Immunopathology</i> , <b>1980</b> , 15, 384-96                         |      | 59 |
| 77 | Endogenous Neoantigen-Specific CD8 T Cells Identified in Two Glioblastoma Models Using a Cancer Immunogenomics Approach. <i>Cancer Immunology Research</i> , <b>2016</b> , 4, 1007-1015                    | 12.5 | 58 |
| 76 | Prolongation of cardiac and islet allograft survival by a blocking hamster anti-mouse CXCR3 monoclonal antibody. <i>Transplantation</i> , <b>2008</b> , 86, 137-47   | 1.8  | 58 |
| 75 | Small-animal PET of steroid hormone receptors predicts tumor response to endocrine therapy using a preclinical model of breast cancer. <i>Journal of Nuclear Medicine</i> , <b>2012</b> , 53, 1119-26      | 8.9  | 57 |
| 74 | Assembly of the cytolytic alternative pathway of complement from 11 isolated plasma proteins. <i>Journal of Experimental Medicine</i> , <b>1978</b> , 148, 1722-7  | 16.6 | 57 |
| 73 | Reversal of virus-induced systemic shock and respiratory failure by blockade of the lymphotoxin pathway. <i>Nature Medicine</i> , <b>1999</b> , 5, 1370-4  | 50.5 | 55 |
| 72 | Prevention of the graft-versus-host reaction in newborn mice by antibodies to tumor necrosis factor-alpha. <i>Transplantation</i> , <b>1989</b> , 47, 1057-61  | 1.8  | 55 |
| 71 | The role of C3 fragments in endocytosis and extracellular cytotoxic reactions by polymorphonuclear leukocytes. <i>Clinical Immunology and Immunopathology</i> , <b>1982</b> , 23, 335-57                   |      | 55 |

|    |   |      |    |
|----|---|------|----|
| 70 | Alternative pathway of complement: demonstration and characterization of initiating factor and its properdin-independent function. <i>Journal of Experimental Medicine</i> , <b>1976</b> , 144, 1062-75   | 16.6 | 54 |
| 69 | Interleukin 12 stimulates IFN-gamma-mediated inhibition of tumor-induced regulatory T-cell proliferation and enhances tumor clearance. <i>Cancer Research</i> , <b>2009</b> , 69, 8700-9  | 10.1 | 53 |
| 68 | The chemistry and biology of complement receptors. <i>Seminars in Immunopathology</i> , <b>1984</b> , 7, 221-49   |      | 51 |
| 67 | Programmable nanoparticle functionalization for in vivo targeting. <i>FASEB Journal</i> , <b>2013</b> , 27, 255-64  | 0.9  | 50 |
| 66 | Identification of a T cell hybridoma that produces large quantities of macrophage-activating factor. <i>Journal of Experimental Medicine</i> , <b>1982</b> , 156, 677-89  | 16.6 | 50 |
| 65 | Inflammatory monocytes require type I interferon receptor signaling to activate NK cells via IL-18 during a mucosal viral infection. <i>Journal of Experimental Medicine</i> , <b>2017</b> , 214, 1153-1167   | 16.6 | 49 |
| 64 | Identification of the activator system for antibody to Toxoplasma as the classical complement pathway. <i>Journal of Infectious Diseases</i> , <b>1980</b> , 141, 366-9   | 7    | 48 |
| 63 | STAT1 deficiency unexpectedly and markedly exacerbates the pathophysiological actions of IFN-alpha in the central nervous system. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2002</b> , 99, 16209-14 | 11.5 | 47 |
| 62 | Enhanced tumorigenesis in HTLV-1 tax-transgenic mice deficient in interferon-gamma. <i>Blood</i> , <b>2004</b> , 104, 3305-11   | 2.2  | 46 |
| 61 | Functional cooperation of the interleukin-2 receptor beta chain and Jak1 in phosphatidylinositol 3-kinase recruitment and phosphorylation. <i>Molecular and Cellular Biology</i> , <b>1998</b> , 18, 6416-22  | 4.8  | 46 |
| 60 | Development and application of an enzyme-linked immunosorbent assay for the quantitation of alternative complement pathway activation in human serum. <i>Journal of Clinical Investigation</i> , <b>1984</b> , 73, 160-70                             | 15.9 | 46 |
| 59 | ABIN-3: a molecular basis for species divergence in interleukin-10-induced anti-inflammatory actions. <i>Molecular and Cellular Biology</i> , <b>2007</b> , 27, 4603-16   | 4.8  | 45 |
| 58 | TAK1 targeting by glucocorticoids determines JNK and IκB regulation in Toll-like receptor-stimulated macrophages. <i>Blood</i> , <b>2010</b> , 115, 1921-31   | 2.2  | 44 |
| 57 | NF-kappa B-inducing kinase regulates selected gene expression in the Nod2 signaling pathway. <i>Infection and Immunity</i> , <b>2006</b> , 74, 2121-7   | 3.7  | 44 |
| 56 | A novel c-Jun-dependent signal transduction pathway necessary for the transcriptional activation of interferon gamma response genes. <i>Journal of Biological Chemistry</i> , <b>2007</b> , 282, 938-46   | 5.4  | 44 |
| 55 | Monoclonal anti-tumor necrosis factor antibody renders non-obese diabetic mice hypersensitive to irradiation and enhances insulinitis development. <i>International Immunology</i> , <b>1992</b> , 4, 611-4   | 4.9  | 41 |
| 54 | The lymphotoxin LTalpha(1)beta(2) controls postnatal and adult spleen marginal sinus vascular structure and function. <i>Immunity</i> , <b>2009</b> , 30, 408-20  | 32.3 | 35 |
| 53 | Selective Blockade of Interferon-β and -γ Reveals Their Non-Redundant Functions in a Mouse Model of West Nile Virus Infection. <i>PLoS ONE</i> , <b>2015</b> , 10, e0128636   | 3.7  | 34 |

|    |   |      |    |
|----|---|------|----|
| 52 | Transforming growth factor beta decreases the immunogenicity of rat islet xenografts (rat to mouse) and prevents rejection in association with treatment of the recipient with a monoclonal antibody to interferon gamma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1990</b> , 87, 1591-5 | 11.5 | 34 |
| 51 | Macrophage I-A/I-E expression and macrophage-stimulating lymphokines in murine lupus. <i>Cellular Immunology</i> , <b>1984</b> , 87, 92-100   | 4.4  | 33 |
| 50 | Response to interferons and antibacterial innate immunity in the absence of tyrosine-phosphorylated STAT1. <i>EMBO Reports</i> , <b>2016</b> , 17, 367-82   | 6.5  | 33 |
| 49 | Detection of neoantigen-specific T cells following a personalized vaccine in a patient with glioblastoma. <i>OncImmunity</i> , <b>2019</b> , 8, e1561106  | 7.2  | 32 |
| 48 | CXCR3 enhances a T-cell-dependent epidermal proliferative response and promotes skin tumorigenesis. <i>Cancer Research</i> , <b>2011</b> , 71, 5707-16  | 10.1 | 32 |
| 47 | Dysregulated STAT1-SOCS1 control of JAK2 promotes mammary luminal progenitor cell survival and drives ER(+) tumorigenesis. <i>Cell Death and Differentiation</i> , <b>2014</b> , 21, 234-46   | 12.7 | 31 |
| 46 | Stat-1 is not essential for inhibition of B lymphopoiesis by type I IFNs. <i>Journal of Immunology</i> , <b>2000</b> , 165, 2362-6  | 5.3  | 30 |
| 45 | Identifying the initiating events of anti-Listeria responses using mice with conditional loss of IFN- $\gamma$ receptor subunit 1 (IFNGR1). <i>Journal of Immunology</i> , <b>2013</b> , 191, 4223-34   | 5.3  | 29 |
| 44 | A completely foreign receptor can mediate an interferon-gamma-like response. <i>EMBO Journal</i> , <b>2001</b> , 20, 5431-42  | 13   | 27 |
| 43 | Dual Requirement of Cytokine and Activation Receptor Triggering for Cytotoxic Control of Murine Cytomegalovirus by NK Cells. <i>PLoS Pathogens</i> , <b>2015</b> , 11, e1005323   | 7.6  | 25 |
| 42 | A novel role for Stat1 in phagosome acidification and natural host resistance to intracellular infection by <i>Leishmania major</i> . <i>PLoS Pathogens</i> , <b>2009</b> , 5, e1000381   | 7.6  | 25 |
| 41 | Enumeration of cytokine-secreting cells at the single-cell level. <i>European Journal of Immunology</i> , <b>1989</b> , 19, 1591-7  | 6.1  | 24 |
| 40 | Cancer immunoediting of the NK group 2D ligand H60a. <i>Journal of Immunology</i> , <b>2011</b> , 187, 3538-45  | 5.3  | 23 |
| 39 | Strain-specific variation in murine natural killer gene complex contributes to differences in immunosurveillance for urethane-induced lung cancer. <i>Cancer Research</i> , <b>2012</b> , 72, 4311-7  | 10.1 | 22 |
| 38 | C3 modified at the thiolester site: acquisition of reactivity with cellular C3b receptors. <i>Bioscience Reports</i> , <b>1981</b> , 1, 873-80  | 4.1  | 22 |
| 37 | Hypocomplementemic glomerulonephritis in an infant and mother. Evidence for an abnormal form of C3. <i>American Journal of Nephrology</i> , <b>1987</b> , 7, 470-7  | 4.6  | 21 |
| 36 | Radiation-induced neoantigens broaden the immunotherapeutic window of cancers with low mutational loads. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2021</b> , 118,  | 11.5 | 20 |
| 35 | Leprosy: altered complement receptors in disseminated disease. <i>Journal of Investigative Dermatology</i> , <b>1985</b> , 85, 58s-61s  | 4.3  | 19 |

|    |  |      |    |
|----|--|------|----|
| 34 | Cancer immunogenomic approach to neoantigen discovery in a checkpoint blockade responsive murine model of oral cavity squamous cell carcinoma. <i>Oncotarget</i> , <b>2018</b> , 9, 4109-4119                                      | 3.3  | 19 |
| 33 | Up-regulation of gamma interferon receptors on the human monocytic cell line U937 by 1,25-dihydroxyvitamin D3 and granulocyte-macrophage colony stimulating factor. <i>Journal of Leukocyte Biology</i> , <b>1988</b> , 44, 187-91 | 6.5  | 18 |
| 32 | The biology and biochemistry of interferon-gamma and its receptor. <i>Gastroenterologia Japonica</i> , <b>1993</b> , 28 Suppl 4, 88-94; discussion 95-6  |      | 17 |
| 31 | Response to the cancer immunosurveillance controversy. <i>Nature Immunology</i> , <b>2004</b> , 5, 4-5   | 19.1 | 16 |
| 30 | Characterization and expression of the human leukocyte-common antigen (CD45) gene contained in yeast artificial chromosomes. <i>Genomics</i> , <b>1991</b> , 10, 756-64  | 4.3  | 16 |
| 29 | The structure and function of interferon-gamma receptors. <i>International Journal of Immunopharmacology</i> , <b>1992</b> , 14, 413-9   |      | 14 |
| 28 | NKG2D-NKG2D Ligand Interaction Inhibits the Outgrowth of Naturally Arising Low-Grade B Cell Lymphoma In Vivo. <i>Journal of Immunology</i> , <b>2016</b> , 196, 4805-13  | 5.3  | 14 |
| 27 | Truncating Prolactin Receptor Mutations Promote Tumor Growth in Murine Estrogen Receptor-Alpha Mammary Carcinomas. <i>Cell Reports</i> , <b>2016</b> , 17, 249-260   | 10.6 | 14 |
| 26 | Enumeration and characterization of human killer and natural killer cells by a modified single-cell assay. <i>Scandinavian Journal of Immunology</i> , <b>1984</b> , 19, 529-39  | 3.4  | 13 |
| 25 | IFN-gamma produced in vivo during the first two days is critical for resolution of murine Leishmania major infections. <i>Microbial Pathogenesis</i> , <b>1993</b> , 14, 495-500   | 3.8  | 12 |
| 24 | Opsonization of bacteroides by the alternative complement pathway reconstructed from isolated plasma proteins. <i>Journal of Experimental Medicine</i> , <b>1987</b> , 165, 777-98   | 16.6 | 12 |
| 23 | Novel non-canonical role of STAT1 in Natural Killer cell cytotoxicity. <i>Oncotarget</i> , <b>2016</b> , 7, 11863-11872  | 7.2  | 10 |
| 22 | A dual function of NKG2D ligands in NK-cell activation. <i>European Journal of Immunology</i> , <b>2012</b> , 42, 2452-8   | 8.1  | 9  |
| 21 | Interferon-D. <b>2003</b> , 567-601  |      | 9  |
| 20 | Response and resistance to interferons and interacting cytokines. <i>Journal of the National Cancer Institute</i> , <b>1995</b> , 87, 257-64   | 9.7  | 9  |
| 19 | Deficiency of erythrocyte C3b receptor (CR1) in AIDS and AIDS-related syndromes. <i>Bioscience Reports</i> , <b>1986</b> , 6, 81-6   | 4.1  | 9  |
| 18 | Abnormal Mammary Development in STAT1-Null Mice is Stroma-Dependent. <i>PLoS ONE</i> , <b>2015</b> , 10, e0129895  | 3.7  | 8  |
| 17 | Cancer vaccines 2004 opening address: the molecular and cellular basis of cancer immunosurveillance and immunoediting. <i>Cancer Immunity</i> , <b>2005</b> , 5 Suppl 1, 1   |      | 6  |

|    |   |     |   |
|----|---|-----|---|
| 16 | Loss of DAP12 and FcR $\gamma$ drives exaggerated IL-12 production and CD8(+) T cell response by CCR2(+) Mo-DCs. <i>PLoS ONE</i> , <b>2013</b> , 8, e76145  | 3-7 | 5 |
| 15 | Novel ER $\alpha$ positive breast cancer model with estrogen independent growth in the bone microenvironment. <i>Oncotarget</i> , <b>2016</b> , 7, 49751-49764  | 3-3 | 5 |
| 14 | Measurement of mouse and human interferon gamma. <i>Current Protocols in Immunology</i> , <b>2001</b> , Chapter 6, Unit 6.8   | 4   | 4 |
| 13 | The role of antibody and complement in lysing virus-infected cells. <i>Medical Microbiology and Immunology</i> , <b>1982</b> , 170, 221-7   | 4   | 4 |
| 12 | A pilot trial of neoantigen DNA vaccine in combination with nivolumab/ipilimumab and prostrvac in metastatic hormone-sensitive prostate cancer (mHSPC).. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, TPS192-TPS192 <sup>4</sup> | 2-2 | 4 |
| 11 | Macrophage activation factor from EL-4, a murine T-cell line: antigenic characterization by hamster monoclonal antibodies to murine interferon-gamma. <i>Cellular Immunology</i> , <b>1987</b> , 107, 340-7                                 | 4-4 | 3 |
| 10 | An Important Role for CD4 T Cells in Adaptive Immunity to <i>Toxoplasma gondii</i> in Mice Lacking the Transcription Factor Batf3. <i>MSphere</i> , <b>2020</b> , 5,  | 5   | 3 |
| 9  | Tumor necrosis factor-alpha prevents rejection of islet xenografts (rat to mouse). <i>Diabetes</i> , <b>1993</b> , 42, 651-657  | 0-9 | 3 |
| 8  | The Chemistry and Biology of Complement Receptors <b>1985</b> , 115-143   |     | 3 |
| 7  | Cancer Immunosurveillance: Immunoediting <b>2016</b> , 396-405  |     | 3 |
| 6  | Abstract 526: Cancer immunoediting by the innate immune system in the absence of adaptive immunity <b>2012</b> ,  |     | 2 |
| 5  | Immunomodulatory antibodies for the treatment of lymphoma: Report on the CALYM Workshop. <i>Oncolimmunology</i> , <b>2016</b> , 5, e1186323   | 7-2 | 2 |
| 4  | The molecular basis of IFN $\alpha$ action. <i>Growth Factors and Cytokines in Health and Disease</i> , <b>1997</b> , 521-556   |     | 1 |
| 3  | IL-12 Stimulates Interferon-Gamma Mediated Inhibition of Tumor-Induced Regulatory T Cell Proliferation and Enhances Tumor Clearance. <i>Blood</i> , <b>2008</b> , 112, 2558-2558  | 2-2 | 1 |
| 2  | BCL6-dependent TCF-1+ progenitor cells maintain effector and helper CD4 T cell responses to persistent antigen  |     | 1 |
| 1  | IFN $\beta$ Receptor-STAT1 Signaling and Cancer Immunoediting <b>2003</b> , 399-418   |     |   |